HealthDay News — Aspirin resistance, measured using the Platelet Function Analyzer (PFA)-100 system, is associated with cardiovascular events in aspirin-treated patients, according to a study published online October 21 in the Journal of Clinical Pharmacy and Therapeutics.
H.Y. Chen, MD, from Taipei City Hospital in Taiwan, and P. Chou, PhD, from the Yang-Ming University School of Medicine in Taiwan, assessed aspirin resistance in 465 aspirin-treated patients from the outpatient department. Patients were followed for 5 years for hospitalization for any acute cardiovascular event.
The researchers found that 20% of the patients had aspirin resistance. There was a strong correlation for prior hospitalization history of cardiovascular events with aspirin resistance (P=0.001). Cardiovascular events had developed in 11 patients with aspirin resistance (8 stroke and three myocardial infarction) and in 9 patients without aspirin resistance (4 stroke and 5 myocardial infarction) at the 5-year follow-up (12.1 versus 2.4%; P<0.001). A strong correlation was seen between aspirin resistance and cardiovascular events at the five-year follow-up in multivariate analysis (adjusted odds ratio, 4.28; 95% confidence interval, 1.64 to 11.2; P=0.03).
“We posit that measuring aspirin resistance by PFA-100 may play a role in clinical cardiovascular prevention,” the authors write.